1. NO
INFINITE
PROBABILITY
DRIVE
INSIDE
UP
TO
200X
FASTER
THAN
CONVENTIONAL
TOOLS
Genalice B.V. the Netherlands confiden'al
WE
HAVE
ALWAYS
THOUGHT
THERE
WAS
SOMETHING
FUNDAMENTALLY
WRONG
WITH
DNA
MAPPING
THE
END
OF
THE
BIG
BAM
THEORY
GENALICE
Building
the
“Google
DNA”
company
ICT
&
MedTech:
new
business
opportuni'es
Jos
Lunenberg
Chief
Business
Officer
2. Today’s
Journey
▲ the
drive
▲ the
opportunity
▲ the
status
▲ the
environment
▲ the
route
▲ the
hurdles
confiden'al
2
5. DNA
3.2
billion
base
pairs
Organized
in
23
chromosome
pairs
The
cause
confiden'al
5
6. The
soluIon
Targeted
treatment
based
on
molecular
profiling
is
the
solu'on
PaIents
with
same
condiIon
DNA
PaIents
with
same
condiIon
Profiling
Good
responders
No
responders
Bad
side
effects
confiden'al
6
10. The
vision
At
the
brink
of
the
BIGGEST
change
in
medicine
Enabled
through
advances
in
DNA
digitaliza'on
and
by
powerful
data
analysis
Sequencing
Adapted
from
“The
Crea've
Destruc'on
of
Medicine”
by
Eric
Topol,
MD
confiden'al
10
Cell
Phone
Personal
Computer
Internet
Digital
Devices
Social
Networks
The
Great
InflecIon
of
Medicine
Accelera.on
of
Technology
1970
1980
1990
2000
2010
2020
11. The
market
developments
Main
sequencing
methods
&
cost
development
11
Company
Method
Sanger
Ins'tute
Sanger
Roche
454
pyro
Illumina
Solexa
Applied
Biosystems
(LT)
SOLiD
Life
Technologies
Ion
Torrent
semiconductor
Complete
Genomics
DNA
nanoball
Helicos
Biosciences
Heliscope
single
molecule
Pacific
Biosciences
Single
molecule
real
'me
(SMRT)
Oxford
Nanopore
Nanopore
DNA
Illumina’s introduction
of the HiSeq X Ten
12. The
momentum
DNA
data
digitalizaIon
is
skyrockeIng
Number
of
sequenced
full
human
genomes
is
exploding
Adapted from Technology Review, May/June 2012, ‘Bases to Bytes’ by Mike Orcutt
confiden'al
12
13. Hans
Karten
(1961)
13
The
wizkid
Chief
ExecuIve
&
Technology
Officer
▲ BSc
Electrical
Engineering
▲ 14
years
career
at
Oracle
Corpora'on,
patentee
of
11
patents
▲ 7
years
pro-‐deo
“Chairman
of
the
Bap'st
Church”
in
Harderwijk
▲ 3
year
technical
due-‐diligences
for
a
Venture
Capitalist
▲ Co-‐founder
of
GENALICE
17. DNA
data
processing
&
analysis
workflow
GENALICE
product
proposi'ons
Individual NGS data
analyses
confiden'al
17
GENALICE MAP
GENALICE LINK
GENALICE CHECK
The
product
porcolio
Downstream
analysis
Clinical
Decision
Support
Preprocessing
Next
GeneraIon
Sequencing
Correlation with
other domains
&
18. MAP
in
overview
Next-‐GeneraIon
Sequencing
data
processing
Preprocessing
components
Preprocessing
Components Alignment Variant calling Annotation
Description Mapping individual
reads on right position
Statistical correction of
detected variants
Variant qualification and
association with existing
knowledge
confiden'al
18
19. IntergalacIc
speed
Up
to
100x
faster
-‐
from
FASTQ
to
VCF
in
30
minutes*
using
a
small
commodity
hardware
server
with
a
dual
Intel
Xeon
E5
processor
*NGS data preprocessing for one full human genome (37x coverage)
confiden'al
19
20. Storage reduction (fold change)
Size
magers
Taking
control
of
the
NGS
big
data
deluge
Human
Up
to
100x
smaller
alignment
output
file
1000 genomes
Cultivated
tomato
Wild
tomato
100
75
50
25
0
100x
71x
15x
ALIGNMENT OUTPUT PER
HUMAN GENOME
400
GB
4
GB
CONVENTIONAL
TOOLS:
GENALICE
MAP:
confiden'al
20
21. Scalable
soluIon
GENALICE
MAP
product
proposiIon
Delivered
in
an
all-‐in-‐one
appliance:
the
GENALICE
VAULT
Product
components:
▲ MAP
nodes
(alignment
&
variant
calling)
▲ CONTROL
node
(workflow
management
&
real-‐'me
monitoring)
▲ GAR
toolkit
(incl.
SAM/BAM/FASTQ
converter
and
IGV
viewer)
Product
features:
▲ Storage
on
board
(incl.
SSDs)
▲ Embedded
Oracle
database
▲ Graphical
User
Interface
▲ High
level
security
XS
S
M
L
XL
2 4
* HGE37 = Human Genome Equivalents with an average of 37x coverage sequenced
# Each MAP server only contains a dual standard INTEL XEON Processor E5-2620
confiden'al
21
Storage
Maximum
number
of
HGE37*
500
1,000
2,500
4,000
10,000
Performance
align
&
call
HGE37/day
average
48
144
240
336
624
minutes
to
align
&
call
a
HGE37
average
30
10
6
4
2
Average
total
realignment
days
for
fully
loaded
appliance
10
7
10
12
16
27. THE
PLAN
Business
Strategy
▲ Key
/
Social
Opinion
Leader
management
▲ Focus
on
high
volume
centers/ini'a'ves
▲ Focus
high
complexity
data
opportuni'es
▲ Disrup've
market
penetra'on
(costly)
▲ Partnerships
with
global
top
ins'tutes
▲ Partnerships
with
key
market
players
(e.g.
Intel,
Illumina)
confiden'al
27
36. Excellent
team
and
network
Our
board
of
directors
confiden'al
36
Former
posiIons:
CEO
of
Crucell
(sold
to
J&J
for
2.4B)
Board
member
Galapagos
(listed
AMEX)
Professor
of
entrepreneurship
at
IESE
Business
School
in
Barcelona
Former
posiIons:
Group
Management
Royal
Philips
Chairman
of
the
Board
at
Crucell
Serial
Enterpreneur
Former
posiIons:
Founder
and
Managing
Director
Tango
and
RouteMobiel
37. Excellent
team
and
network
Our
scien'fic
advisory
board
Prof.
Edwin
Cuppen
UMC
Utrecht
Head
of
Research
Medical
Gene'cs
confiden'al
37
Amsterdam
Prof.
Gerrit
Meijer
VUmc
Amsterdam
Principal
Inves'gator
TraIT
(CTMM)
